Physician profile
Rocco C Piazza
NPI 1346464930
$38,539.11
in general payments reported to CMS, 2019-2025
11 companies · $3,760 in 2025
The $3,760 reported for 2025 was more than what 90% of Plastic and Reconstructive Surgery providers received nationally (typical 2025 total: $445).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $3,734 · 2021: $2,363 · 2022: $2,760 · 2023: $2,303 · 2024: $562 · 2025: $3,760.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,562 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,174 · Consulting Fee: $1,000 · Travel and Lodging: $802 · Gift: $87.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,562.42 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,173.75 |
| Consulting Fee | $1,000.00 |
| Travel and Lodging | $802.00 |
| Gift | $87.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $28,192.96 | 2019-2023 | |
| Merz North America, INC. | $4,916.03 | 2019-2023 | Xeomin |
| Motiva USA, LLC | $2,643.02 | 2025 | |
| Abbvie INC. | $1,773.81 | 2023-2025 | |
| Galderma Laboratories, L.P. | $448.03 | 2020-2023 | |
| Abbott Laboratories | $143.28 | 2024 | Proclaim |
| Mentor Worldwide LLC | $124.99 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $110.91 | 2021 | |
| Bard Peripheral Vascular, INC. | $110.00 | 2021 | |
| Integra Lifesciences Corporation | $38.68 | 2025 | Integra, Omnigraft, Integra Dermal Regeneration Template |
| Davol INC. | $37.40 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rocco Piazza listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.